Licensing Income from Intellectual Property
First written in FY2016-Q3. 5 of 8 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2025.
1 other company's latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In the Value Chain Business, although some facilities reached the end of their contracted facility operations and management periods, royalty revenue from Medigen and medical device sales were generated.」
Royalty revenue from Medigen contributed to annual Value Chain Business sales as revenue generated through the utilization of intellectual property. - FY2025-H1AdvancedAnnual report
「The Value Chain Business generated royalty revenue from Medigen and sales of medical devices, among other revenue.」
Royalty revenue from Medigen was generated, updating the track record of revenue from the utilization of intellectual property. - FY2023RestatedAnnual report
「Revenue from the regenerative medicine products business was ¥0.4 million, an increase of 111.2% year on year.」
Revenue from the regenerative medicine products business remained small and was disclosed as sales from licensing revenue and other sources. - FY2020-Q3RestatedAnnual report
「Subsequently, in March 2020, the technology transfer of the gamma-delta T-cell culture and processing technology that the companies had been jointly developing was completed. As a result, once approved by the Taiwanese authorities, cancer immunocellular therapy using this technology will be provided to patients through medical institutions affiliated with MBC, and the company will receive royalties from MBC based on the number of cultures processed using the gamma-delta T-cell culture and processing technology.」
The completion of the transfer of the gamma-delta T-cell culture and processing technology to MBC and the framework for collecting royalties based on the number of cultures processed are reiterated. - FY2020-Q2AdvancedAnnual report
「In March 2020, the technology transfer of the gamma-delta T-cell culture and processing technology that the companies had been jointly developing was completed. As a result, once approved by the Taiwanese authorities, cancer immunocellular therapy using this technology will be provided to patients through medical institutions affiliated with MBC, and the company will receive royalties from MBC based on the number of cultures processed using the gamma-delta T-cell culture and processing technology.」
The technology transfer of the gamma-delta T-cell culture and processing technology to MBC was completed, establishing a specific framework for providing the therapy after approval by the Taiwanese authorities and collecting royalties based on the number of cultures processed. - FY2020-Q1AdvancedAnnual report
「In October 2019, the company agreed to license its gamma-delta T-cell culture and processing technology for cancer indications to Medigen Biotechnology Corporation (基亞生物科技股份有限公司), a company listed on the Taipei Exchange and based in Taipei, and entered into a licensing agreement with the company, hereinafter "MBC." Under the agreement, the company will receive royalties from MBC based on the number of cell cultures processed using the gamma-delta T-cell culture and processing technology.」
The company entered into a licensing agreement with MBC for its gamma-delta T-cell culture and processing technology, establishing a specific framework for royalty revenue based on the number of cultures processed. - FY2019-Q2AdvancedAnnual report
「In January 2019, the company entered into a licensing agreement with US-based BioLegend to develop research-use products using a novel monoclonal antibody owned by the company.」
The company entered into a specific licensing agreement with BioLegend to develop research-use products using its novel monoclonal antibody. - FY2016-Q3First statedAnnual report
「We also generated license revenue from intellectual property acquired to date.」
The Company is working to generate license revenue from intellectual property it has acquired.